Drugs / trabedersen
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00844064 | Jan 2005 → Nov 2011 | colorectal neoplasm, melanoma, pancreatic neoplasm | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06579196 | May 2025 → Mar 2028 expected | non-small cell lung carcinoma | University of Nebraska | Recruiting | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT05425576 | Jun 2025 → Dec 2028 expected | malignant pleural mesothelioma | Oncotelic Inc. | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05935774 | Dec 2023 → Jul 2028 | non-small cell lung carcinoma | University of Washington | Withdrawn | No outcome recorded |
| Phase 2 | NCT04801017 | Apr → Aug 2021 | COVID-19 | Oncotelic Inc. | Unknown | No outcome recorded |
| Phase 2 | NCT00431561 | Apr 2003 → Mar 2009 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00761280 | Dec 2008 → Feb 2012 | anaplastic astrocytoma, glioblastoma | Isarna Therapeutics GmbH | Terminated | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06079346 Comparator | May 2024 → Jun 2026 overdue | pancreatic ductal adenocarcinoma | Oncotelic Inc. | Recruiting | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 9 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | trabedersen | “AP 12009 (trabedersen), dose escalation scheme, continuous intravenous infusion (7 days), every other week, up to 10 cycles.” NCT00844064 ↗4“10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks” NCT00431561 ↗ |
| Known as | A-12009 FREE ACID | ChEMBL registry synonym — accepted as the source's own label CHEMBL2108345 ↗ |
| Known as | AP 12009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00431561 ↗ |
| Known as | OT-101 | “Trabedersen (OT-101) is a synthetic antisense oligodeoxynucleotide that specifically inhibits the production of Transforming growth factor-beta 2 (TGF-β2).” NCT06579196 ↗4“trabedersen (OT-101) in combination with atezolizumab” NCT05935774 ↗ |
| Action | Inhibit | “OT-101, a TGF-b2 inhibitor” NCT05425576 ↗ |
| Modality | Antisense oligonucleotide | “AP 12009 is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor-beta2 (TGF-beta2).” NCT00431561 ↗ |
| Route | Other | “10 µM AP 12009 (trabedersen), intratumoral infusion, every other week, 11 cycles, maximum 21 weeks” NCT00431561 ↗ |
| Target | TGFB2 | “AP 12009 is a phosphorothioate antisense oligodeoxynucleotide specific for the mRNA of human transforming growth factor-beta2 (TGF-beta2).” NCT00431561 ↗ |